Description: Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Home Page: www.venusmedtech.com
No. 88, Jiangling Road
Hangzhou,
31005
China
Phone:
86 57 1877 72180
Officers
| Name | Title |
|---|---|
| Mr. Min Zeng | Exec. Chairman |
| Mr. Zhenjun Zi | Founder, GM & Exec. Director |
| Mr. Haiyue Ma | CFO & Joint Company Sec. |
| Mr. Hou-Sen Lim MEng. | COO, CTO & Exec. Director |
| Joyce Heo | Director of Sales |
| Mr. Christopher Lee Richardson | Head of U.S. Operations |
| Mr. Amir Gross | Head of Venus Global Heart Valve Innovation Center |
| Shakeel Osman | Sr. VP of Sales Europe |
| Mr. Wai Chiu Wong FCS | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 38.3142 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2063 |
| Price-to-Sales TTM: | 15.1735 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1039 |